JSR and SymBiosis took part in an $18.5m series C extension for PureTech spinoff Vedanta, growing the Bristol-Myers Squibb and PureTech Health-backed round to $45.5m.

The immunotherapy developer, which is exploits Yale University research and counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.

The series A, led by corporate venturing unit GV, may not have been last week’s largest deal, but Verve’s tie-up with fellow Harvard spinout Beam Therapeutics tells an intriguing story.

JD.com has secured CICC Capital, Baring Private Equity Asia and CPEChina Fund for a series A round expected to value its healthcare spinoff at $6.9bn.

The Posco-backed pulmonary device maker has collected $65m in an oversubscribed round led by Ally Bridge Group, taking its equity funding to $135m to date.

The immunotherapy developer, which counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.

Lundbeck-backed pruritus therapy developer Trevi Therapeutics raised $55m when it floated, but had to price its shares significantly below its range.

The Optum-backed round was led by Leerink Transformation Partners and will fund the home medical test provider's international expansion plans.

Hanwha Asset Management contributed to a round that boosted the online life insurance provider's overall funding to about $140m.

GumGum's dental tools spinoff has raised $11m from Craft Ventures and undisclosed strategic dental industry partners.